These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36228375)

  • 1. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
    Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
    Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-mediated activation of hypoxia-inducible factor-1α in triple-negative breast cancer: A review.
    Liu L; Bai J; Hu L; Jiang D
    Medicine (Baltimore); 2023 Oct; 102(43):e35493. PubMed ID: 37904441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.
    Srivastava N; Usmani SS; Subbarayan R; Saini R; Pandey PK
    Front Oncol; 2023; 13():1199105. PubMed ID: 37492478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-induced autophagy in triple negative breast cancer: association with prognostic variables, patients' survival and response to neoadjuvant chemotherapy.
    El-Guindy DM; Ibrahim FM; Ali DA; El-Horany HE; Sabry NM; Elkholy RA; Mansour W; Helal DS
    Virchows Arch; 2023 May; 482(5):823-837. PubMed ID: 36939902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway.
    Li H; Sun X; Li J; Liu W; Pan G; Mao A; Liu J; Zhang Q; Rao L; Xie X; Sheng X
    Neoplasia; 2022 Oct; 32():100821. PubMed ID: 35985176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
    Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
    Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q
    Yang HL; Lin PY; Vadivalagan C; Lin YA; Lin KY; Hseu YC
    Arch Toxicol; 2023 Apr; 97(4):1047-1068. PubMed ID: 36847822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential mechanism of HIF-1α and CD147 in the development of triple-negative breast cancer.
    Chen M; Liu Z; Zheng K; Hu C; Peng P
    Medicine (Baltimore); 2024 Jun; 103(23):e38434. PubMed ID: 38847725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer.
    Du Y; Wei N; Ma R; Jiang S; Song D
    Cell Death Dis; 2020 Sep; 11(9):731. PubMed ID: 32908121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.
    Fang W; Liao C; Shi R; Simon JM; Ptacek TS; Zurlo G; Ye Y; Han L; Fan C; Bao L; Ortiz CL; Lin HR; Manocha U; Luo W; Peng Y; Kim WY; Yang LW; Zhang Q
    Elife; 2021 Nov; 10():. PubMed ID: 34779768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cross-communication of HIF-1α and HIF-2α with Wnt signaling in TNBC and influence of hypoxic microenvironment in the formation of an organ-on-chip model of breast cancer.
    Banerjee M; Devi Rajeswari V
    Med Oncol; 2023 Jul; 40(8):245. PubMed ID: 37454033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mitochondrial calcium uniporter regulates breast cancer progression via HIF-1α.
    Tosatto A; Sommaggio R; Kummerow C; Bentham RB; Blacker TS; Berecz T; Duchen MR; Rosato A; Bogeski I; Szabadkai G; Rizzuto R; Mammucari C
    EMBO Mol Med; 2016 May; 8(5):569-85. PubMed ID: 27138568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.
    Bailey CM; Liu Y; Peng G; Zhang H; He M; Sun D; Zheng P; Liu Y; Wang Y
    Nanomedicine; 2020 Oct; 29():102278. PubMed ID: 32738299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
    da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
    Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment.
    Zhi S; Chen C; Huang H; Zhang Z; Zeng F; Zhang S
    Front Immunol; 2024; 15():1370800. PubMed ID: 38799423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-1α inhibitor YC-1 suppresses triple-negative breast cancer growth and angiogenesis by targeting PlGF/VEGFR1-induced macrophage polarization.
    Li Y; Zhang MZ; Zhang SJ; Sun X; Zhou C; Li J; Liu J; Feng J; Lu SY; Pei-Jun L; Wang JC
    Biomed Pharmacother; 2023 May; 161():114423. PubMed ID: 36822023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition.
    Jampasri S; Reabroi S; Tungmunnithum D; Parichatikanond W; Pinthong D
    Molecules; 2022 Sep; 27(17):. PubMed ID: 36080483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
    Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
    J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis.
    Chourasia AH; Tracy K; Frankenberger C; Boland ML; Sharifi MN; Drake LE; Sachleben JR; Asara JM; Locasale JW; Karczmar GS; Macleod KF
    EMBO Rep; 2015 Sep; 16(9):1145-63. PubMed ID: 26232272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development.
    Ghosh R; Samanta P; Sarkar R; Biswas S; Saha P; Hajra S; Bhowmik A
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.